S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

$18.24
+1.59 (+9.55%)
(As of 03/27/2024 ET)
Today's Range
$16.64
$18.54
50-Day Range
$14.82
$20.18
52-Week Range
$12.95
$25.47
Volume
1.01 million shs
Average Volume
886,201 shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.25

Arcus Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
126.2% Upside
$41.25 Price Target
Short Interest
Bearish
16.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Arcus Biosciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$320 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.16) to ($2.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.23 out of 5 stars

Medical Sector

554th out of 939 stocks

Pharmaceutical Preparations Industry

257th out of 422 stocks

RCUS stock logo

About Arcus Biosciences Stock (NYSE:RCUS)

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Stock Price History

RCUS Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Navigating 5 Analyst Ratings For Arcus Biosciences
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
RCUS Mar 2024 30.000 call
RCUS Mar 2024 20.000 put
RCUS Mar 2024 10.000 call
RCUS Mar 2024 12.500 call
DTIL Mar 2024 2.500 put
See More Headlines
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
577
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.25
High Stock Price Target
$70.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+126.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-307,000,000.00
Net Margins
-262.39%
Pretax Margin
-257.27%

Debt

Sales & Book Value

Annual Sales
$117 million
Book Value
$6.17 per share

Miscellaneous

Free Float
78,326,000
Market Cap
$1.66 billion
Optionable
Optionable
Beta
0.82
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives


RCUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCUS shares.
View RCUS analyst ratings
or view top-rated stocks.

What is Arcus Biosciences' stock price target for 2024?

8 analysts have issued 12-month target prices for Arcus Biosciences' stock. Their RCUS share price targets range from $23.00 to $70.00. On average, they anticipate the company's share price to reach $41.25 in the next twelve months. This suggests a possible upside of 126.2% from the stock's current price.
View analysts price targets for RCUS
or view top-rated stocks among Wall Street analysts.

How have RCUS shares performed in 2024?

Arcus Biosciences' stock was trading at $19.10 at the beginning of the year. Since then, RCUS shares have decreased by 4.5% and is now trading at $18.24.
View the best growth stocks for 2024 here
.

When is Arcus Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RCUS earnings forecast
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Wednesday, February, 21st. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.01. The firm had revenue of $31 million for the quarter, compared to analyst estimates of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative trailing twelve-month return on equity of 57.17%. The company's revenue for the quarter was down 8.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.93) EPS.

What ETFs hold Arcus Biosciences' stock?
What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?
When did Arcus Biosciences IPO?

Arcus Biosciences (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.25%), Vanguard Group Inc. (5.15%), Octagon Capital Advisors LP (2.50%), Dimensional Fund Advisors LP (2.13%), Decheng Capital LLC (1.16%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Alexander Azoy, Carolyn C Tang, Carolyn C Tang, Gilead Sciences, Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends
.

How do I buy shares of Arcus Biosciences?

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:RCUS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners